Anika Therapeutics (ANIK) Given Daily Media Impact Score of 0.25

News coverage about Anika Therapeutics (NASDAQ:ANIK) has trended positive on Saturday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Anika Therapeutics earned a daily sentiment score of 0.25 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 45.959962915856 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the headlines that may have impacted Accern Sentiment’s scoring:

Several research analysts have recently commented on the stock. BidaskClub upgraded shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 8th. Zacks Investment Research upgraded shares of Anika Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 2nd.

Shares of Anika Therapeutics (NASDAQ ANIK) traded up 0.27% on Friday, hitting $52.82. 489,516 shares of the stock traded hands. The firm has a market capitalization of $774.24 million, a PE ratio of 23.47 and a beta of 1.69. The firm’s 50 day moving average is $49.79 and its 200 day moving average is $47.14. Anika Therapeutics has a 52 week low of $41.38 and a 52 week high of $53.99.

Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings results on Wednesday, July 26th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.32. Anika Therapeutics had a net margin of 30.44% and a return on equity of 14.88%. The firm had revenue of $33.50 million for the quarter, compared to analyst estimates of $27.20 million. During the same period in the prior year, the firm posted $0.57 earnings per share. The company’s quarterly revenue was up 25.9% compared to the same quarter last year. On average, analysts expect that Anika Therapeutics will post $2.20 EPS for the current fiscal year.

In other Anika Therapeutics news, CEO Charles H. Sherwood sold 14,201 shares of the company’s stock in a transaction on Wednesday, July 5th. The shares were sold at an average price of $50.03, for a total transaction of $710,476.03. Following the sale, the chief executive officer now directly owns 246,740 shares of the company’s stock, valued at $12,344,402.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffery S. Thompson sold 10,725 shares of the company’s stock in a transaction on Monday, May 22nd. The stock was sold at an average price of $47.39, for a total transaction of $508,257.75. Following the sale, the director now directly owns 15,845 shares in the company, valued at $750,894.55. The disclosure for this sale can be found here. Insiders have sold 88,725 shares of company stock worth $4,459,085 over the last ninety days. Insiders own 6.57% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Anika Therapeutics (ANIK) Given Daily Media Impact Score of 0.25” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Insider Buying and Selling by Quarter for Anika Therapeutics (NASDAQ:ANIK)

What are top analysts saying about Anika Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Anika Therapeutics Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit